Welcome to our dedicated page for XCELERATE news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on XCELERATE stock.
XCELERATE INC (XCRT) is a healthcare services and products company that focuses on integrating innovative technologies into the medical field. Established with a mission to revolutionize clinical care through the application of advanced engineering and intellectual property, Xcelerate operates in three main business areas:
- Medical Technology and Virtual Health Services: Xcelerate is dedicated to extending the reach of physicians through AI and virtual health technology, especially targeting patients in developing countries.
- Consumer Health and Beauty Products: The company formulates, packages, and markets clinically tested health and beauty products, including the Ceramedx® line, which features plant-based ceramide therapy for dry and sensitive skin.
- Owning and Licensing Medical Equipment: Xcelerate holds and licenses various forms of medical equipment and a portfolio of patents and technology licenses.
Notable achievements include the recent publication of two utility patent applications by the United States Patent and Trademark Office, and the company's selection as an approved vendor for the Army & Air Force Exchange Service. Xcelerate is also actively involved in enhancing investor relations with the help of Darrow Associates and has partnered with Craft Capital Management to facilitate capital raising and advisory services.
With its headquarters in Mauldin, SC, Xcelerate is poised for significant growth and continues to develop its diverse range of healthcare solutions to improve global medical care.
Xcelerate, Inc. (OTCQB:XCRT) has announced the appointment of Fabian Urquijo to its Xcelerate Brands Advisory Board. Urquijo, an experienced marketing professional, brings 21 years of expertise from Procter & Gamble and Revlon, where he held senior marketing roles. His background includes managing various product categories, helping shape brand strategy, and driving innovation. CEO Michael O'Shea noted that Urquijo's experience is expected to support the development of a new portfolio of clean skin and personal care products. Furthermore, Urquijo will play a key role as Xcelerate moves forward with due diligence for acquiring a controlling interest in The ESN Group.
Xcelerate, Inc. (OTCQB:XCRT) has executed a letter of intent to acquire a controlling interest in ESN Group, Inc., which specializes in health care and skin care products. This acquisition is currently in a 60-day due diligence phase, aiming to finalize transaction agreements. ESN operates two revenue-generating brands: Ceramedx, known for its facial cleansers utilizing exclusive natural ceramide technology, and Earth Science Beauty, offering plant-based personal care solutions. If successful, the deal is projected to contribute millions in first-year revenue to Xcelerate. The company is also forming a division to expand its healthcare product lines.
Xcelerate, Inc. (OTCQB:XCRT) CEO Mike O'Shea provided a shareholder update on January 3, 2023, reflecting on a busy 2022. Key achievements include:
- Qualified a Regulation A offering with the SEC.
- Acquired AfiyaSasa Africa LLC and a patent portfolio from HS Pharmaceuticals.
- Patented a surgical tool enhancing precision.
- Uplisted to OTCQB and removed 'shell company' status.
In 2023, Xcelerate aims to generate revenue through a new subsidiary, Xcelerate Brands, and launch the AfiyaSasa program in Q2.
Xcelerate, Inc. (OTCQB:XCRT) announced its initiative to develop over-the-counter healthcare products utilizing its patent portfolio acquired from HS Pharmaceutical. Following productive meetings with HS Pharmaceuticals’ staff, the company aims to identify marketing and manufacturing partners to bring these products to market. The acquisition represents significant investment and research. CEO Michael O'Shea highlighted the potential for generating revenue in the near term through this initiative.
Xcelerate (OTCQB:XCRT) announced the granting of patent protection in nine additional countries, enhancing its intellectual property portfolio. This includes a Korean patent for a nanosilica composition aimed at stimulating T lymphocytes to treat conditions like cancer and inflammatory diseases. Further, a Eurasian patent has been approved covering several countries, including Russia and Kazakhstan. Xcelerate's CEO, Michael O'Shea, emphasized ongoing collaborative efforts with U.S. research institutions to advance its R&D initiatives.
Xcelerate, Inc. (OTCQB:XCRT) has received approval from the OTC Market Group to uplist to the OTCQB Venture Market. Trading will commence on August 1, 2022. CEO Michael O'Shea emphasized that this move aims to enhance transparency and liquidity for shareholders, while expanding the company’s reach to potential investors. The OTCQB is recognized by the SEC and serves as a public market for early-stage companies, requiring compliance with stringent disclosure and financial standards. Xcelerate operates in the medical industry, focusing on medical equipment rights and virtual health technology development.
Xcelerate, Inc. (OTC PINK:XCRT) has announced its application to upgrade its common stock trading from the OTC Pink Market to the OTCQB Venture Market. This move is aimed at enhancing visibility and liquidity for investors as it prepares to develop a pilot program in Africa via its subsidiary, AfiyaSasa Africa, LLC, and advance its portfolio of medical technology patents acquired from HS Pharmaceuticals. The approval for this listing remains pending with the OTCQB.
Xcelerate (OTC PINK:XCRT) announced the appointment of Cathy Scangarella to its Advisory Board, effective immediately. Scangarella, the Chief Business Development Officer at Choose New Jersey, brings over 25 years of experience in marketing and outreach, enhancing business development strategies nationally and internationally. Her expertise includes establishing collaborations with research universities and industry partnerships. Xcelerate's CEO, Michael O'Shea, emphasized her valuable skill set to advance the company's patent development following a recent acquisition from HS Pharmaceuticals.
Xcelerate, Inc. (OTC Pink: XCRT) has announced the acquisition of a significant patent portfolio from HS Pharmaceuticals, aimed at advancing innovative medical technologies. CEO Michael O’Shea and HS Pharmaceuticals CEO Jon Wilken discussed this strategic move in a recent interview, emphasizing the potential for collaboration in developing groundbreaking treatments, particularly in chronic wound care and oncology. This acquisition follows over two years of negotiations and aligns with Xcelerate's mission to incorporate cutting-edge innovations into the medical field, addressing critical health challenges.
Xcelerate, Inc. (OTC PINK:XCRT) has announced the acquisition of a portfolio of patents and technology licenses from HS Pharmaceuticals LLC, focusing on oncology and healthcare products. Mr. Jon Wilken, former President and CEO of BILO Inc., is joining Xcelerate's Board of Directors. Wilken brings 30 years of experience in retail and will assist in integrating the acquired patents into Xcelerate's business strategy. The company has also acquired a 51% stake in AfiyaSasa Africa, LLC, a medical technology firm leveraging AI and AR.
FAQ
What is the current stock price of XCELERATE (XCRT)?
What is the market cap of XCELERATE (XCRT)?
What does Xcelerate Inc. do?
How does Xcelerate contribute to healthcare?
What recent patents has Xcelerate published?
What are the key product lines of Xcelerate?
Who are Xcelerate's strategic partners?
Where is Xcelerate's headquarters located?
What is the significance of Xcelerate's partnership with the Army & Air Force Exchange Service?
How does Xcelerate plan to grow its business?
What are the company’s financial goals?
How can investors stay updated on Xcelerate's developments?
